If we consider that FKBP52 modulates Tau aggregation synergistically with other FKBPs/chaperones in the lysosomal environment in order to degrade these aggregates, we might also suppose that its decreased expression in AD brain neurons could disturb this highly regulated process. The gene discussed is MAPT; the disease is Alzheimer disease.